Why Cassava Sciences Shares Are Soaring Higher
Why Cassava Sciences Shares Are Soaring Higher
Cassava Sciences Inc (NASDAQ:SAVA) shares are trading higher by 7.15 to $49.48 during Wednesday's pre-market session after Biogen Inc (NASDAQ:BIIB) and Eisai Co. Ltd. (OTC:ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer's treatment candidate.
Cassava Sciences is also developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
What Happened?
Biogen and Eisai announced Lecanemab treatment met the primary endpoint and reduced clinical decline on the global cognitive and functional scale, CDR-SB, compared with placebo at 18 months by 27%, which represents a treatment difference in the score change of -0.45 (p=0.00005) in the analysis of Intent-to-treat (ITT) population.
The companies said starting as early as six months, across all time points, the treatment showed highly statistically significant changes in CDR-SB from baseline compared to placebo (all p-values are less than 0.01).
In addition, all key secondary endpoints were also met with highly statistically significant results compared with placebo (p<0.01).
"Today's announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer's disease, and provide a clinically meaningful impact on cognition and function," said Michel Vounatsos, Chief Executive Officer at Biogen.
See Also: If You Invested $1,000 In Tesla, AMD, Nvidia, Apple, Microsoft, Amazon And Plug Power Shares 10 Years Ago, Here's How Much You'd Have Now
According to data from Benzinga Pro, Cassava Sciences Inc has a 52-week high of $100.00 and a 52-week low of $13.84.
木薯科學公司 (納斯達克代碼:SAVA) 在周三的上市前交易時段內,股價上漲 7.15 至 49.48 美元 生物科技公司 (納斯達克:比 IB) 和 永彩股份有限公司有限公司 OTC:ESALY)宣布了週二晚些時候對阿爾茨海默氏症候選人的一項後期研究的陽性結果。
木薯科學還開發了一種科學方法,用於治療和檢測阿爾茨海默氏病。其治療性候選產品稱為 simufilam,是一種針對阿爾茨海默氏病的新型治療方法;研究性診斷候選產品稱為 SavADX,它是一種新穎的方法,可以在臨床症狀明顯出現之前幾年,從一小部分血液樣本中檢測阿爾茨海默氏病的存在。
發生了什麼事?
Biogen 和 Eisai 宣布,與 18 個月的安慰劑相比,萊卡尼邁抗治療達到了主要終點,並減少了全球認知和功能規模 CDR-SB 的臨床下降,與 18 個月的安慰劑相比減少了 27%,這代表了意圖治療(ITT)人口分析中 -0.45(p=0.00005)的分數變化的治療差異。
這些公司表示,最早從六個月開始,在所有時間點上,與安慰劑相比,該治療顯示 CD-SB 從基線上具有極高的統計學顯著變化(所有 p 值都小於 0.01)。
此外,與安慰劑 (p<0.01) 相比,所有關鍵的次要端點也得到了高度統計顯著的結果。
「今天的宣布使患者及其家人希望,如果獲得批准,lecanemab 可能減緩阿爾茨海默氏病的進展,並對認知和功能產生臨床意義的影響,」說 米歇尔·沃納索斯,生物元首席執行官。
另請參閱:如果您在 10 年前在特斯拉,AMD,Nvidia,蘋果,微軟,亞馬遜和插頭電源股票上投資了 1000 美元,這是您現在擁有多少
根據從本辛加臨數據, 木薯科學公司有 52 周高點 $100.00 和 52 周低點 $13.84.
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧